Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Real world use of sutimlimab in patients with cold agglutinin disease: An international study

Blood (2025) 146 (Supplement 1): 1100.

https://doi.org/10.1182/blood-2025-1100

Published: 2025

Journal Articles

Easix, a new tool to predict response and refractoriness in immune-mediated thrombotic thrombocytopenic purpura

Blood (2025) 146 (Supplement 1): 6661.

https://doi.org/10.1182/blood-2025-6661

Published: 2025

Journal Articles

Long-term efficacy and safety of rilzabrutinib, an oral bruton tyrosine kinase (BTK) inhibitor in patients with warm autoimmune hemolytic anemia (wAIHA) in the LUMINA Phase 2b part B study: A 74-week follow-up

Bruno Fattizzo, Henrik Frederiksen, Alessandro Lucchesi, Bing Han, Catherine Broome, Nicola Cooper, Joan Cid, Frederick Chen, Amitabha Mazumder, Míriam Vara Pampliega, Deepthi Jayawardene, Heidi Krenz, Jing Zhao, Ahmed Daak, David Kuter

Blood (2025) 146 (Supplement 1): 4655.

https://doi.org/10.1182/blood-2025-4655

Published: 2025

Journal Articles

Real-world safety of sutimlimab in patients with CAD/CAS: A multinational, multi-center, observational, prospective cohort Study

Alexander Röth, Marc Michel, Wilma Barcellini, Ulrich Jaeger, Yasutaka Ueda, Quentin A. Hill, Joan Cid, Kelley Dacus, Mounia Beloueche, Catherine Broome

Blood (2025) 146 (Supplement 1): 6242.

https://doi.org/10.1182/blood-2025-6242

Published: 2025

Journal Articles

Expanding the boundaries of CAR T-cell therapy: Implementation of an outpatient-at-home (OATH) model

Blood (2025) 146 (Supplement 1): 6192.

https://doi.org/10.1182/blood-2025-6192

Published: 2025

Journal Articles

Part a Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Patients with Warm Autoimmune Hemolytic Anemia (wAIHA): Multicenter, Open-Label, Phase 2b Study

Nichola Cooper, David J Kuter, Henrik Frederiksen, Bing Han, Frederick Chen, Wilma Barcellini, Joan Cid, Catherine M. Broome, Míriam Vara, Amitabha Mazumder, Alessandro Lucchesi, Xin Zhao, Antonio M Risitano, Sumit Sawhney, Quentin A. Hill, Deepthi Jayawardene, Remco Diab, Jing Zhao, Ahmed Daak

Blood (2024) 144 (Supplement 1): 3836.

https://doi.org/10.1182/blood-2024-200325

Published: 2024

Journal Articles

First Interim Analysis of Patients with Cold Agglutinin Disease (CAD) Patients and the Sutimlimab-Treated Subgroup from the Cadence Registry

Catherine M. Broome, Marc Michel, Wilma Barcellini, Ulrich Jaeger, Yasutaka Ueda, Quentin A. Hill, Joan Cid, Jiangming Wu, Shruti Srivastava, Marek Wardęcki, Reena Patel, Ronnie Yoo, Alexander Röth

Blood (2024) 144 (Supplement 1): 7667.

https://doi.org/10.1182/blood-2024-206942

Published: 2024

Journal Articles

Outcomes of 9/10 Mmud Allo-HCT Using Ptcy-TK Prophylaxis. Results from a Single Institution

Filipe Pinto, Alexandra Pedraza, Maria Suarez-Lledo, Laia Guardia, Paola Charry, Joan Cid, Miquel Lozano, Gerard Corrius, Noemí De Llobet, Enric Carreras, Laura Rosiñol Dachs, Francesc Fernández-Avilés, Montserrat Rovira, Carmen Martinez, Maria Queralt Salas, Jordi Esteve Reyner

Blood (2024) 144 (Supplement 1): 7342.

https://doi.org/10.1182/blood-2024-207563

Published: 2024

Journal Articles

Frailty Syndrome Is Associated with Increased Endothelial Activation and Post-Transplant Complications in Allo-HCT Patients

Blood (2024) 144 (Supplement 1): 3510.

https://doi.org/10.1182/blood-2024-207118

Published: 2024

Journal Articles

Transforming Frailty Care in Allo-HCT Candidates: A Prospective Assessment of a Tele-Prehabilitation Project

Blood (2024) 144 (Supplement 1): 787.

https://doi.org/10.1182/blood-2024-204867

Published: 2024

Journal Articles

ADAMTS13 recovery in acute thrombotic thrombocytopenic purpura after caplacizumab therapy

Blood (2024) 143 (18): 1807–1815.

https://doi.org/10.1182/blood.2023022725

Published: 2024

Includes: Supplemental data

Journal Articles

ARI0002h (Cesnicabtagene Autoleucel), an Academic Point-of-Care B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Strategy: Activity and Safety after Fractionated Initial Therapy and Booster Dose in 60 Patients with Relapsed/Refractory Multiple Myeloma

Blood (2023) 142 (Supplement 1): 1026.

https://doi.org/10.1182/blood-2023-180828

Published: 2023

Journal Articles

Allogeneic Hematopoietic Cell Transplantation with Sequential-Based Conditioning in Refractory / Relapsed Acute Myeloid Leukemia: Experience from a Single Institution

Blood (2023) 142 (Supplement 1): 3550.

https://doi.org/10.1182/blood-2023-179852

Published: 2023

Journal Articles

Caplacizumab Treatment in Elderly Patients with iTTP: Updated Experience from the Spanish TTP Registry

Blood (2023) 142 (Supplement 1): 5429.

https://doi.org/10.1182/blood-2023-180970

Published: 2023

Journal Articles

Effect of Caplacizumab in the Recovery of ADAMTS13 Level in Patients with Autoimmune Thrombotic Thrombocytopenic Purpura. Analysis from the Spanish Registry (REPTT)

Blood (2023) 142 (Supplement 1): 5394.

https://doi.org/10.1182/blood-2023-182876

Published: 2023

Journal Articles

Post-Transplant Cyclophosphamide-Based Prophylaxis and Its Impact on the Immune Reconstitution and the Incidence of Infectious Complications

Blood (2023) 142 (Supplement 1): 2200.

https://doi.org/10.1182/blood-2023-186687

Published: 2023

Journal Articles

Impact of Ptcy-Based Prophylaxis on Early Infectious Complications in Adults Undergoing Peripheral Blood Allo-HCT

Blood (2022) 140 (Supplement 1): 4730–4732.

https://doi.org/10.1182/blood-2022-170498

Published: 2022

Journal Articles

Impressive Reduction of Gvhd Incidence Using Ptcy-TK for Gvhd Prevention in Adults Undergoing 10/10 HLA-Matched Peripheral Blood Allo-HCT

María Queralt Salas, Paola Charry, Nuria Martínez-Cibrian, María Suárez-Lledó, Luis Gerardo Rodríguez-Lobato, Marc Brusosa, María Teresa Solano, Meritxell Nomdedeu, Joan Cid, Miquel Lozano, Jordi Arcarons, Noemí Llobet, Laura Rosinol Dachs, Jordi Esteve, Álvaro Urbano-Ispizua, Enric Carreras, Francesc Fernández-Avilés, Maria Carmen Martinez Munoz, Montserrat Rovira

Blood (2022) 140 (Supplement 1): 4772–4773.

https://doi.org/10.1182/blood-2022-170407

Published: 2022

Journal Articles

Easix Application in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Prophylaxis

Blood (2022) 140 (Supplement 1): 7616–7618.

https://doi.org/10.1182/blood-2022-167051

Published: 2022

Journal Articles

Sustained Complement C1s Inhibition with Sutimlimab in Patients with Cold Agglutinin Disease Results in Continued Efficacy during Part B of the Randomized Placebo-Controlled Phase 3 Cadenza Study (NCT03347422)

Blood (2022) 140 (Supplement 1): 2825–2827.

https://doi.org/10.1182/blood-2022-159562

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Real world use of sutimlimab in patients with cold agglutinin disease: An international study

Easix, a new tool to predict response and refractoriness in immune-mediated thrombotic thrombocytopenic purpura

Long-term efficacy and safety of rilzabrutinib, an oral bruton tyrosine kinase (BTK) inhibitor in patients with warm autoimmune hemolytic anemia (wAIHA) in the LUMINA Phase 2b part B study: A 74-week follow-up

Real-world safety of sutimlimab in patients with CAD/CAS: A multinational, multi-center, observational, prospective cohort Study

Expanding the boundaries of CAR T-cell therapy: Implementation of an outpatient-at-home (OATH) model

Part a Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Patients with Warm Autoimmune Hemolytic Anemia (wAIHA): Multicenter, Open-Label, Phase 2b Study

First Interim Analysis of Patients with Cold Agglutinin Disease (CAD) Patients and the Sutimlimab-Treated Subgroup from the Cadence Registry

Outcomes of 9/10 Mmud Allo-HCT Using Ptcy-TK Prophylaxis. Results from a Single Institution

Frailty Syndrome Is Associated with Increased Endothelial Activation and Post-Transplant Complications in Allo-HCT Patients

Transforming Frailty Care in Allo-HCT Candidates: A Prospective Assessment of a Tele-Prehabilitation Project

ADAMTS13 recovery in acute thrombotic thrombocytopenic purpura after caplacizumab therapy

ARI0002h (Cesnicabtagene Autoleucel), an Academic Point-of-Care B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Strategy: Activity and Safety after Fractionated Initial Therapy and Booster Dose in 60 Patients with Relapsed/Refractory Multiple Myeloma

Allogeneic Hematopoietic Cell Transplantation with Sequential-Based Conditioning in Refractory / Relapsed Acute Myeloid Leukemia: Experience from a Single Institution

Caplacizumab Treatment in Elderly Patients with iTTP: Updated Experience from the Spanish TTP Registry

Effect of Caplacizumab in the Recovery of ADAMTS13 Level in Patients with Autoimmune Thrombotic Thrombocytopenic Purpura. Analysis from the Spanish Registry (REPTT)

Post-Transplant Cyclophosphamide-Based Prophylaxis and Its Impact on the Immune Reconstitution and the Incidence of Infectious Complications

Impact of Ptcy-Based Prophylaxis on Early Infectious Complications in Adults Undergoing Peripheral Blood Allo-HCT

Impressive Reduction of Gvhd Incidence Using Ptcy-TK for Gvhd Prevention in Adults Undergoing 10/10 HLA-Matched Peripheral Blood Allo-HCT

Easix Application in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Prophylaxis

Sustained Complement C1s Inhibition with Sutimlimab in Patients with Cold Agglutinin Disease Results in Continued Efficacy during Part B of the Randomized Placebo-Controlled Phase 3 Cadenza Study (NCT03347422)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only